SWOG-9133 RT w/ or w/o Doxorubicin and Vinblastine in Stage I or Stage II Hodgkin's Disease

PHASE3CompletedINTERVENTIONAL
Enrollment

348

Participants

Timeline

Start Date

September 30, 1992

Primary Completion Date

November 30, 2000

Study Completion Date

April 30, 2014

Conditions
Lymphoma
Interventions
DRUG

doxorubicin hydrochloride

25 mg/m\^2 on days 1 and 15

DRUG

vinblastine

6 mg/m\^2 on days 1 and 15

RADIATION

standard subtotal nodal irradiation

3600-4000 cGy delivered over 20 fractions

Trial Locations (22)

10029

Mount Sinai Medical Center, NY, New York

11030

CCOP - North Shore University Hospital, Manhasset

13210

State University of New York - Upstate Medical University, Syracuse

19899

CCOP - Christiana Care Health Services, Wilmington

33140

CCOP - Mount Sinai Medical Center, Miami Beach

38163

University of Tennessee, Memphis Cancer Center, Memphis

52242

University of Iowa Hospitals and Clinics, Iowa City

55455

University of Minnesota Cancer Center, Minneapolis

60637

University of Chicago Cancer Research Center, Chicago

63110

Barnes-Jewish Hospital, St Louis

65203

Ellis Fischel Cancer Center - Columbia, Columbia

89106

CCOP - Southern Nevada Cancer Research Foundation, Las Vegas

92093-0658

University of California San Diego Cancer Center, La Jolla

20307-5000

Walter Reed Army Medical Center, Washington D.C.

01655

University of Massachusetts Memorial Medical Center, Worcester

03756

Norris Cotton Cancer Center, Lebanon

14263-0001

Roswell Park Cancer Institute, Buffalo

27104-4241

CCOP - Southeast Cancer Control Consortium, Winston-Salem

27157-1082

Comprehensive Cancer Center of Wake Forest University Baptist Medical Center, Winston-Salem

02903

Rhode Island Hospital, Providence

05401-3498

Vermont Cancer Center, Burlington

23298-0037

MBCCOP - Massey Cancer Center, Richmond

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

collaborator

Cancer and Leukemia Group B

NETWORK

lead

SWOG Cancer Research Network

NETWORK

NCT00002495 - SWOG-9133 RT w/ or w/o Doxorubicin and Vinblastine in Stage I or Stage II Hodgkin's Disease | Biotech Hunter | Biotech Hunter